PARP1 and skin basal cell carcinoma: Recently, Sahu et al. have evaluated the clinical efficacy of FCM and PARPi-FL, an exogenous nuclear poly-(ADP-ribose) polymerase (PARP1)-targeted BODIPY in 95 fresh-discarded BCC surgical specimens [78].